CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 6 incoming connections
- ScaleMarket cap is $1.76B, above the global median of $1.18B
- PositionReturn on equity is -50.3%, lower than 95% of its Diagnostics & Research peers (median 2.1%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.76BUSDvs all stocks (USD)
Revenue (TTM)
69.67MUSDvs all stocks (USD)
Profit Margin
-153.84%vs Diagnostics & Research peers
Beta
2.32xvs all stocks
52-Week Change
159.22%vs all stocks
Market Capitalization
1.76BUSDvs all stocks (USD)
Enterprise Value
1.58BUSDvs all stocks (USD)
Forward P/E
-17.48xvs Diagnostics & Research peers
Price to Sales (TTM)
25.23xvs Diagnostics & Research peers
Price to Book (MRQ)
7.44xvs Diagnostics & Research peers
Enterprise to Revenue
22.73xvs Diagnostics & Research peers
Enterprise to EBITDA
-15.14xvs Diagnostics & Research peers
Gross Margin
21.21%vs Diagnostics & Research peers
Profit Margin
-153.84%vs Diagnostics & Research peers
Operating Margin
-150.25%vs Diagnostics & Research peers
Return on Assets (TTM)
-25.03%vs Diagnostics & Research peers
Return on Equity (TTM)
-50.32%vs Diagnostics & Research peers
Revenue (TTM)
69.67MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.7130USDUpdated Sep 27, 2026Quarterly Revenue Growth
30.00%vs Diagnostics & Research peers
Gross Profit (TTM)
8.84MUSDvs all stocks (USD)
EBITDA (TTM)
-104.60MUSDvs all stocks (USD)
Net Income (TTM)
-107.18MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-92.30MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-56.03MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Diagnostics & Research peers
Revenue
69.65MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
53.87MUSDFY2025 · Dec 31, 2025Gross Profit
15.78MUSDFY2025 · Dec 31, 2025Operating Income
-88.06MUSDvs all stocks (USD)
Pre-tax Income
-81.25MUSDFY2025 · Dec 31, 2025Income Tax Expense
21.00KUSDFY2025 · Dec 31, 2025Net Income
-81.27MUSDFY2025 · Dec 31, 2025EBIT
-81.04MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-71.00MUSDFY2025 · Dec 31, 2025Research & Development
50.26MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
53.57MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
7.16MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
205.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-81.27MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-71.04MUSDFY2025 · Dec 31, 2025Free Cash Flow
-75.54MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
126.03MUSDFY2025 · Dec 31, 2025Income Tax Paid
23.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-81.27MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
10.05MUSDFY2025 · Dec 31, 2025Stock-based Compensation
9.43MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.03MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-8.06MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.55MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.76MUSDFY2025 · Dec 31, 2025Capital Expenditures
-4.50MUSDFY2025 · Dec 31, 2025Purchase of Investments
-210.17MUSDFY2025 · Dec 31, 2025Sale of Investments
192.11MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-22.57MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
2.59MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-2.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-189.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
127.19MUSDFY2025 · Dec 31, 2025Shares Outstanding
106.37MSharesUpdated Sep 27, 2026Float Shares
86.37MSharesUpdated Sep 27, 2026Shares Short
8.27MSharesUpdated Sep 27, 2026Short Ratio
2.25daysvs all stocks
Short % of Shares Outstanding
12.09%vs all stocks
% Held by Insiders
26.15%vs all stocks
% Held by Institutions
66.78%vs all stocks
Total Cash (MRQ)
212.66MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.99USDUpdated Sep 27, 2026Total Debt (MRQ)
38.00MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1616xvs Diagnostics & Research peers
Current Ratio (MRQ)
5.28xvs Diagnostics & Research peers
Book Value per Share (MRQ)
2.21USDUpdated Sep 27, 2026Total Assets
334.16MUSDvs all stocks (USD)
Total Current Assets
267.95MUSDFY2025 · Dec 31, 2025Total Liabilities
72.98MUSDFY2025 · Dec 31, 2025Total Non-current Assets
66.21MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
33.35MUSDFY2025 · Dec 31, 2025Total Current Liabilities
39.63MUSDFY2025 · Dec 31, 2025Cash
4.92MUSDFY2025 · Dec 31, 2025Cash Equivalents
119.33MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
124.25MUSDFY2025 · Dec 31, 2025Other Short-term Investments
115.71MUSDFY2025 · Dec 31, 2025Accounts Receivable
16.20MUSDFY2025 · Dec 31, 2025Inventory
5.26MUSDFY2025 · Dec 31, 2025Accounts Payable
12.99MUSDFY2025 · Dec 31, 2025Short-term Debt
8.08MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.56MUSDFY2025 · Dec 31, 2025Other Current Liabilities
5.46MUSDFY2025 · Dec 31, 2025Long-term Debt
31.87MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.48MUSDFY2025 · Dec 31, 2025Common Stock (Book)
10.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-631.26MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
261.19MUSDvs all stocks (USD)
52-Week Low
4.96USDUpdated Sep 27, 202652-Week High
18.89USDUpdated Sep 27, 202652-Week Change
159.22%vs all stocks
Beta
2.32xvs all stocks
50-Day MA
15.09USDUpdated Sep 27, 2026200-Day MA
10.31USDUpdated Sep 27, 2026Avg 10-Day Volume
2.22MSharesUpdated Sep 27, 2026Avg 30-Day Volume
3.21MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-1.09USDUpdated Sep 27, 2026Other Income / Expense
-142.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -50.3%, lower than 95% of its Diagnostics & Research peers (median 2.1%)Significant
Return on equity: -0.50Industry median: 0.02Industry P5: -0.23Peers compared: 29.00
Return on assets is -25%, lower than 95% of its Diagnostics & Research peers (median 1.2%)Significant
Return on assets: -0.25Industry median: 0.01Industry P5: -0.20Peers compared: 29.00
Financial Health
Altman Z-Score 12.04: safe zoneNotable
Altman Z-Score: 12.04
Supply Chain
Midstream position: 6 outgoing, 6 incoming connectionsNotable
Outgoing: 6.00Incoming: 6.00
High connectivity hub: 12 industry connectionsNotable
Total Connections: 12.00
Scale
Market cap is $1.76B, above the global median of $1.18BNotable
Market cap (USD): 1,757,925,893Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen Jame Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Milkyway Intelligent Equipment Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowSenseMaking
Ennoconn Corporation
Tier 1ProductionThroughput-Bound ConversionFlowRule
Chongqing Three Gorges Water Conservancy and Electric Power Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Shenzhen Dynanonic Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingFlow
Osaka Soda Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Darbond Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Dongguan Tarry Electronics Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Chambal Fertilisers and Chemicals Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Lier Chemical Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Iovance Biotherapeutics, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Absci Corporation
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Relay Therapeutics Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity